TB Vaccine Offers Zimbabwe Hope

2026-10-19

Hope has earned a foothold. The experimental M72/AS01 tuberculosis vaccine has shown a favourable safety profile in people living with HIV who receive antiretroviral therapy, giving Zimbabwe reason to follow its development closely without mistaking tolerability for protection. That distinction matters. A vaccine can clear a safety assessment while still needing evidence that it prevents disease in the population studied.

The biology warrants caution. HIV damages immune defences, including CD4 T cells, which help control Mycobacterium tuberculosis, the bacterium responsible for TB; antiretroviral therapy suppresses HIV but does not eliminate tuberculosis risk. Prevention therefore remains unfinished. M72/AS01 combines a recombinant fusion protein containing bacterial antigens with an adjuvant system designed to strengthen immune responses, rather than using a live tuberculosis organism. Safety is one question. Whether those responses translate into fewer cases of active TB among people with HIV requires a separate clinical answer.

Zimbabwe needs evidence, not shortcuts. The finding supports further investigation in a group facing heightened TB risk, but it should not be read as proof of protection for everyone with HIV, particularly those outside the treatment conditions assessed. Existing care still counts. Antiretroviral treatment, TB screening and preventive treatment remain part of established care while an experimental vaccine undergoes evaluation for benefits as well as harms. The promise carries a condition. Between an injection that can be tolerated and an illness that can be prevented lies the distance this vaccine must still travel.

Recommendations